🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Hanmi Pharmaceutical Company clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA and UK registers with Hanmi Pharmaceutical Company as lead sponsor. Synced 26 Sep 2026
7Current trials
5Recruiting now
2Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Hanmi Pharmaceutical Company is the lead sponsor of 7 current clinical trials in our USA and UK registers. 5 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are HM15275 and Pembrolizumab. The most-studied condition is Advanced or Metastatic Solid Tumors.

ClinicalTrials.gov trials by status

  • Recruiting571%
  • Active, closed229%

Trials by phase

  • Phase 2457%
  • Phase 1343%
01

Clinical trials sponsored by Hanmi Pharmaceutical Company

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
NCT04775706 · ClinicalTrials.gov ↗ · Short Bowel Syndrome
Phase 2 Recruiting 2022-03 UK, USA
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
NCT06234397 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors
Phase 1 Recruiting 2023-12 USA
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
NCT07527650 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus, T2DM
Drug: HM15275
Phase 2 Recruiting 2026-05 USA
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
NCT07219589 · ClinicalTrials.gov ↗ · Obesity, Obese
Phase 1 Recruiting 2025-11 USA
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT06724016 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors
Phase 1 Recruiting 2024-12 USA
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
NCT04732416 · ClinicalTrials.gov ↗ · Congenital Hyperinsulinism
Phase 2 Active, closed 2022-05 UK, USA
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
NCT07205900 · ClinicalTrials.gov ↗ · Obese, Obesity
Drug: HM15275
Phase 2 Active, closed 2025-12 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Hanmi Pharmaceutical Company trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Hanmi Pharmaceutical Company trials

7 conditions
Advanced or Metastatic Solid Tumors2Obese2Obesity2Short Bowel Syndrome1Congenital Hyperinsulinism1Type 2 Diabetes Mellitus1T2DM1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA75
Clinical trials in UK21

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced or Metastatic Solid Tumors

SponsorTrials
Erasca1

Sponsors with the most current trials registered for this condition.

06

Questions about Hanmi Pharmaceutical Company trials

How many clinical trials does Hanmi Pharmaceutical Company sponsor?

Hanmi Pharmaceutical Company is the lead sponsor of 7 current trials on ClinicalTrials.gov in our USA and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Hanmi Pharmaceutical Company trials recruiting?

Yes. 5 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hanmi Pharmaceutical Company testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are HM15275 (2) and Pembrolizumab (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.